Gossamer Bio ties $250m financing to seralutinib FDA milestones after unusual Phase 3 result
Gossamer Bio’s structured financing provides $25 million initially, another $125 million if FDA accepts the seralutinib NDA in 2026 and potentially $100 million more following approval.